We are looking for a creative, energetic, dedicated and motivated team player, who is enthusiastic about joining and propelling a project in a vibrant field of cardiovascular research.
Within the consortium we will provide a network of experts jointly working on the interface of basic regulatory mechanisms of cardiac disease, bio-engineering and clinical translation. The successful candidate will be involved in all aspects of the project, from performing in vitro assays on optimizing miRNA and biomaterial combinations, cell based assays on biocompatibility and efficacy, to performing and evaluating pre-clinical experiments using a relevant large animal model.
A MRI-guided, minimally invasive strategy to deliver the miRNA-UPy-Gel formulation intramyocardially will be developed. Delivery efficiency, therapeutic and off-target effects will be analysed to evaluate potential enhancements of therapeutic miRNA applications in a pre-clinical setting.
The project will be carried out in close collaboration with local and (inter)national research groups with expertise in miRNA biology, bioengineering and translational research.
Research within the UMC Utrecht concentrates on specific focus areas including Circulatory Health and Regenerative Medicine. The Department of Cardiology has a strong record of research within these focus areas, investigating and developing novel treatment options for cardiovascular disease using cell based and compound driven approaches, state-of-the-art imaging and biomaterials in relevant pre-clinical models.
Within a multi-partner CVON (Cardiovasculaire Onderzoek Nederland) funded consortium (REMAIN project) we aim at assessing how microRNAs (miRNAs), as important regulators and modulators of onset and progression of cardiac disease, can be employed efficiently. Since systemic delivery of these drugs reduce cardiac exposure and can introduce unwanted side effects in extracardiac tissues, we will formulate miRNAs in a pH-responsive supramolecular hydrogel (UPy-Gel) as a localized cardiac delivery vehicle. Synergistic in vitro experiments, and in vivo efficacy studies in a porcine model of ischemic injury will allow us to study potentially enhanced efficacy of hydrogel-based delivery of miRNA therapeutics to improve cardiac regeneration after ischemic injury. REMAIN consortium partners are: Hubrecht lab (Prof E. van Rooij), TU Eindhoven (Prof P. Dankers) and UMCU Cardiology (Prof S. Chamuleau).
The candidate should have a M.D. or M.Sc. in (bio)medical sciences. Candidates are preferred to be communicative, well organized, creative and capable of working independently. Experience with cell culture, methods of molecular biology, flow cytometry, histology and preclinical models (art. 9 certification) is a plus. Fluency in (scientific) writing and speaking English is desirable.
Interested candidates should send (1) a CV including an overview of past research activities and contact details of at least two references, and (2) transcript of MSc degree to dr. K. Neef (firstname.lastname@example.org). Screening of applications will start as soon as applications are received and will continue until the position is filled. The preferred starting date is October 2017.
The maximum salary for this position (100%) is € 2.903,00 gross per month based on full-time employment (work week 36 hours). This job is based on a temporary position for 3 years.
If you have any questions about this vacancy, please contact Mr.dr. K. Neef, Postdoc, phone 088-7567903. Email email@example.com.
Acquisition based on this jobopening is not appreciated.